How Common are Aortic Aneurysms?
Discussion
Aortic root dilatation or thoracic aortic aneurysm occurs in 6:100,000 individuals > 50 years of age. It is due to aging, hypertension, hypercholesterolemia, and smoking. Tertiary syphilis was a cause in the preantibiotic era.
Pediatric aneurysms are very uncommon but the exact prevalence is different due to the various causes. Aneurysms are due to genetic disorders, congenital anomalies or post-surgical repair. In pediatric patients with sudden cardiac deaths, 5.4% are due to ruptured thoracic aortic aneurysms.
Learning Point
Some causes of pediatric aneurysms include:
Familial thoracic aneurysm and dissect...
Source: PediatricEducation.org - February 22, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
Upsides, Downsides for TAVR, Minimally Invasive AVR Upsides, Downsides for TAVR, Minimally Invasive AVR
Minimally invasive aortic valve replacement seems to be associated with a lower risk of midterm mortality, while TAVR was associated with shorter hospitalizations and a lower risk of AKI, in a meta-analysis.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - February 19, 2021 Category: Intensive Care Tags: Cardiology News Source Type: news
SAVR an Option for Many Low-Risk Patients Excluded From Clinical Trials SAVR an Option for Many Low-Risk Patients Excluded From Clinical Trials
Many patients who are excluded from clinical trials comparing transcatheter aortic-valve replacement with surgical aortic-valve replacement appear to do well with the latter approach, according to researchers in Canada.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - January 20, 2021 Category: Surgery Tags: Cardiology News Source Type: news
Houston Methodist first in Houston to perform TriClip procedure
(Houston Methodist) Cardiologists at Houston Methodist recently performed the first catheter-based repair in Houston of a leaky tricuspid valve using the novel TriClip system. Using cardiac ultrasound guidance, doctors were able to implant two TriClip devices in a 75-year-old patient as part of the pivotal TRILUMINATE trial, which seeks to evaluate the safety and efficacy of the device. The tricuspid valve has traditionally required conventional open-heart surgery to repair or replace it. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 13, 2021 Category: International Medicine & Public Health Source Type: news
Structural Valve Deterioration at 5 Years of TAVR Versus SAVR Structural Valve Deterioration at 5 Years of TAVR Versus SAVR
Does bioprosthetic valve failure occur more frequently with transcatheter aortic valve replacement compared with surgical replacement?Journal of the American College of Cardiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 8, 2021 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
TAVR Volumes in the U.S. Have Risen Each Year Since 2011
THURSDAY, Nov. 19, 2020 -- The volume of transcatheter aortic valve replacement (TAVR) procedures in the United States increased from 2011 to 2019, exceeding surgical aortic valve replacements in 2019, and 30-day mortality and stroke rates have... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 19, 2020 Category: Pharmaceuticals Source Type: news
New XARELTO ® (rivaroxaban) Peripheral Artery Disease (PAD) Data from EXPLORER Clinical Research Program to be Unveiled at American Heart Association (AHA) Scientific Sessions 2020
RARITAN, N.J., November 9, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that 10 data presentations will be shared at the virtual American Heart Association (AHA) Scientific Sessions 2020 from November 13-17. Most notably, four new sub-analyses of XARELTO® (rivaroxaban) from the landmark VOYAGER PAD trial, part of the EXPLORER global cardiovascular research program, will be presented, including two live, featured science oral presentations. “We're pleased VOYAGER PAD was selected to be front and center once again at a major medical congress, as there's an urgent need for data in ...
Source: Johnson and Johnson - November 9, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Opioid epidemic leads to more, younger people having heart valve operations
ROCHESTER, Minn. ? The opioid epidemic in the U.S. is becoming a bigger problem medically, socially and financially, and the COVID-19 pandemic has made it worse, according to the Food and Drug Administration. Heart surgeons have seen a disturbing trend over the past decade: more and younger patients with infective endocarditis requiring heart surgery. Infective [...] (Source: Mayo Clinic Minnesota News)
Source: Mayo Clinic Minnesota News - October 28, 2020 Category: Hospital Management Source Type: news
Janssen Submits Application to U.S. FDA for New Indication to Expand Use of XARELTO ® (rivaroxaban) in Patients with Peripheral Artery Disease
RARITAN, NJ, October 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a new indication to expand the use of XARELTO® (rivaroxaban) in patients with peripheral artery disease (PAD). If approved, this new indication for the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 75-100 mg once daily) would include reducing the risk of major thrombotic vascular events such as heart attack, stroke and amputation in patients after recent lower-extremity revascularization, a c...
Source: Johnson and Johnson - October 26, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Survival Rate of Heart Valve Replacement Surgery
Title: Survival Rate of Heart Valve Replacement SurgeryCategory: Diseases and ConditionsCreated: 10/23/2020 12:00:00 AMLast Editorial Review: 10/23/2020 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - October 23, 2020 Category: Cardiology Source Type: news
Results from the REFLECT II Trial reported at TCT Connect
(Cardiovascular Research Foundation) The REFLECT II randomized clinical trial evaluating the safety and efficacy of a device designed to reduce cerebral embolization and ischemic stroke, complications of transcatheter aortic valve replacement (TAVR), found that the device met the primary safety endpoint compared to historical controls but did not demonstrate superiority of the device for the primary hierarchical efficacy endpoint. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 15, 2020 Category: International Medicine & Public Health Source Type: news
New bioprosthetic valve for TAVR fails to demonstrate non-inferiority
(Cardiovascular Research Foundation) In a randomized clinical trial, SCOPE II, a new self-expanding bioprosthetic valve used in transcatheter aortic valve replacement (TAVR) failed to demonstrate non-inferiority compared to an existing self-expanding valve. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 15, 2020 Category: International Medicine & Public Health Source Type: news
Medtronic Launches Head-to-Head TAVR Study Comparing the Evolut(TM) TAVR Platform Against the Edwards SAPIEN Valve in Small Annulus Patients
Medtronic Also Begins Feasibility Study of Evolut TAVR System in Moderate and Asymptomatic Aortic Stenosis Patients
DUBLIN, Oct. 14, 2020 -- (Healthcare Sales & Marketing Network) -- Medtronic plc (NYSE:MDT), a global leader in structural heart therapi... Devices, Interventional, Cardiology Medtronic, transcatheter aortic valve replacement (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 14, 2020 Category: Pharmaceuticals Source Type: news
Outcomes Worse for Deferred Aortic Valve Replacement
FRIDAY, Oct. 2, 2020 -- For patients with symptomatic severe aortic stenosis, deferred aortic valve replacement (AVR) is associated with an increased risk for hospitalization for valve-related symptoms or worsening heart failure, according to a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 2, 2020 Category: Pharmaceuticals Source Type: news
